Globotriaosylceramide leads to K(Ca)3.1 channel dysfunction: a new insight into endothelial dysfunction in Fabry disease

Cardiovasc Res. 2011 Feb 1;89(2):290-9. doi: 10.1093/cvr/cvq333. Epub 2010 Oct 21.

Abstract

Aims: Excessive endothelial globotriaosylceramide (Gb3) accumulation is associated with endothelial dysfunction and impaired endothelium-dependent relaxation in Fabry disease. In endothelial cells, K(Ca)3.1 channels contribute to endothelium-dependent relaxation. However, the effect of Gb3 on K(Ca)3.1 channels and the underlying mechanisms of Gb3-induced dysfunction are unknown. Herein, we hypothesized that Gb3 accumulation induces K(Ca)3.1 channel dysfunction and aimed to clarify the underlying mechanisms.

Methods and results: The animal model of Fabry disease, α-galactosidase A (Gla) knockout mice, displayed age-dependent K(Ca)3.1 channel dysfunction. K(Ca)3.1 current and the channel expression were significantly reduced in mouse aortic endothelial cells (MAECs) of aged Gla knockout mice, whereas they were not changed in MAECs of wild-type and young Gla knockout mice. In addition, K(Ca)3.1 current and the channel expression were concentration-dependently reduced in Gb3-treated MAECs. In both Gb3-treated and aged Gla knockout MAECs, extracellular signal-regulated kinase (ERK) and activator protein-1 (AP-1) were down-regulated and repressor element-1 silencing transcription factor (REST) was up-regulated. Gb3 inhibited class III phosphoinositide 3-kinase and decreased intracellular levels of phosphatidylinositol 3-phosphate [PI(3)P]. In addition, endothelium-dependent relaxation was significantly attenuated in Gb3-treated mouse aortic rings.

Conclusion: Gb3 accumulation reduces K(Ca)3.1 channel expression by down-regulating ERK and AP-1 and up-regulating REST and the channel activity by decreasing intracellular levels of PI(3)P. Gb3 thereby evokes K(Ca)3.1 channel dysfunction, and the channel dysfunction in vascular endothelial cells may contribute to vasculopathy in Fabry disease.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cells, Cultured
  • Class III Phosphatidylinositol 3-Kinases / metabolism
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Endothelial Cells / drug effects
  • Endothelial Cells / metabolism*
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / metabolism*
  • Endothelium, Vascular / physiopathology
  • Extracellular Signal-Regulated MAP Kinases / metabolism
  • Fabry Disease / enzymology
  • Fabry Disease / genetics
  • Fabry Disease / metabolism*
  • Fabry Disease / physiopathology
  • Intermediate-Conductance Calcium-Activated Potassium Channels / metabolism*
  • Membrane Potentials
  • Mice
  • Mice, Knockout
  • Phosphatidylinositol Phosphates / metabolism
  • Repressor Proteins / metabolism
  • Signal Transduction
  • Transcription Factor AP-1 / metabolism
  • Trihexosylceramides / metabolism*
  • Vasodilation
  • Vasodilator Agents / pharmacology
  • alpha-Galactosidase / genetics
  • alpha-Galactosidase / metabolism

Substances

  • Intermediate-Conductance Calcium-Activated Potassium Channels
  • Kcnn4 protein, mouse
  • Phosphatidylinositol Phosphates
  • RE1-silencing transcription factor
  • Repressor Proteins
  • Transcription Factor AP-1
  • Trihexosylceramides
  • Vasodilator Agents
  • phosphatidylinositol 3-phosphate
  • globotriaosylceramide
  • Class III Phosphatidylinositol 3-Kinases
  • Extracellular Signal-Regulated MAP Kinases
  • alpha-Galactosidase